Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Calciphylaxis
Interventions: Sodium Thiosulfate, Placebo-Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Jacksonville, Florida • Chicago, Illinois • Maywood, Illinois + 9 more

Conditions: Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Pembrolizumab, paricalcitol, placebo; Drug
Lead sponsor: Translational Genomics Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Scottsdale, Arizona • Duarte, California • Westwood, Kansas + 3 more

Conditions: Breast Cancer
Interventions: Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Post Operative Pain
Interventions: Bupivacaine, normal saline 0.9%; Drug
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Toledo, Ohio

Conditions: Nasal Polyps
Interventions: Depemokimab (GSK3511294), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more

Conditions: Hip Arthroplasty
Interventions: Extended Release Epidural Morphine (EREM), Placebo; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Calcinosis Cutis
Interventions: Sodium Thiosulfate, Saline Solution; Drug · Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Osteoarthritis of the Knee
Interventions: FX006, Placebo, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more

Conditions: Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neuromuscular Blockade
Interventions: Sugammadex, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epistaxis
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boardman, Ohio • Youngstown, Ohio

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Ipilimumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Burbank, California • Monterey, California + 21 more

Conditions: Quality of Recovery, Same Day Surgery, Nausea and Vomiting, Postoperative, Vaginal Prolapse
Interventions: Dexamethasone, Normal saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Clostridium Difficile
Interventions: SER-109, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Oceanside, California • Sacramento, California • Ventura, California + 26 more

Conditions: Pain
Interventions: Saline Solution for Injection, Exparel; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Interventions: Mesenchymal Stem Cells, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catheter Occlusion, Thrombosis
Interventions: CUSA-081, Placebo, Alteplase; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more

Conditions: Mastectomy, Breast Cancer
Interventions: Liposomal bupivacaine, Standard bupivacaine, Placebo; Drug · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Volunteers
Interventions: SL-325, Placebo (Normal Saline); Biological · Other
Lead sponsor: Shattuck Labs, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Restless Legs Syndrome (RLS)
Interventions: Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more

Conditions: Mumps
Interventions: CVM150, CVM26, Placebo; Biological · Other
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 29 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina

Conditions: Acute Pain
Interventions: IV acetaminophen + 0.5 mg IV hydromorphone, Normal saline + 0.5 mg IV hydromorphone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bronchiolitis, Viral
Interventions: Magnesium Sulfate; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 1 Month to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Acute Alcohol Withdrawal
Interventions: Dexmedetomidine, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

Sugammadex as Rescue Therapy

Intranasal TXA for Anterior Epistaxis in the Emergency Department

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

EXPAREL for Minimally Invasive Supracervical Hysterectomies

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo

Phase 1 Study of SL-325 in Healthy Volunteers

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

IV Acetaminophen as an Analgesic Adjunct

Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis

Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal